Baldwin Wealth Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Baldwin Wealth Partners’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$6.56K	–	289
2024 Q3	$6.56K	Hold	500	–	–	﹤0.01%	846
2024 Q2	$7.03K	Hold	500	–	–	﹤0.01%	566
2024 Q1	$8.45K	Hold	500	–	–	﹤0.01%	568
2023 Q4	$7.06K	Hold	500	–	–	﹤0.01%	603
2023 Q3	$5.15K	Hold	500	–	–	﹤0.01%	625
2023 Q2	$8.24K	Hold	500	–	–	﹤0.01%	609
2023 Q1	$4.58K	Hold	500	–	–	﹤0.01%	683
2022 Q4	$3.58K	Buy	500 +100	+25%	+$701	﹤0.01%	689
2022 Q3	$2K	Hold	400	–	–	﹤0.01%	612
2022 Q2	$1K	Hold	400	–	–	﹤0.01%	661
2022 Q1	$3K	Hold	400	–	–	﹤0.01%	623
2021 Q4	$3K	Hold	400	–	–	﹤0.01%	588
2021 Q3	$4K	Hold	400	–	–	﹤0.01%	582
2021 Q2	$3K	Hold	400	–	–	﹤0.01%	606
2021 Q1	$4K	Hold	400	–	–	﹤0.01%	567
2020 Q4	$3K	Sell	400 -400	-50%	-$2.5K	﹤0.01%	510
2020 Q3	$4K	Hold	800	–	–	﹤0.01%	479
2020 Q2	$6K	Hold	800	–	–	﹤0.01%	460
2020 Q1	$6K	Hold	800	–	–	﹤0.01%	457
2019 Q4	$6K	Hold	800	–	–	﹤0.01%	471
2019 Q3	$3K	Hold	800	–	–	﹤0.01%	487
2019 Q2	$2K	Hold	800	–	–	﹤0.01%	493
2019 Q1	$1K	Hold	800	–	–	﹤0.01%	496
2018 Q4	$2K	Sell	800 -8,500	-91%	-$28.9K	﹤0.01%	483
2018 Q3	$41K	Hold	9,300	–	–	0.01%	336
2018 Q2	$57K	Hold	9,300	–	–	0.01%	298
2018 Q1	$68K	Hold	9,300	–	–	0.01%	267
2017 Q4	$76K	Hold	9,300	–	–	0.01%	265
2017 Q3	$98K	Hold	9,300	–	–	0.02%	237
2017 Q2	$103K	Hold	9,300	–	–	0.02%	235
2017 Q1	$90K	Hold	9,300	–	–	0.01%	247
2016 Q4	$97K	Hold	9,300	–	–	0.02%	231
2016 Q3	$115K	Buy	9,300 +5,000	+116%	+$65.3K	0.02%	217
2016 Q2	$46K	Hold	4,300	–	–	0.01%	277
2016 Q1	$47K	Buy	+4,300	New	+$42.7K	0.01%	306
2014 Q1	–	Sell	-12,600	Closed	-$101K	–	242
2013 Q4	$101K	Sell	12,600 -16,150	-56%	-$114K	0.02%	232
2013 Q3	$189K	Hold	28,750	–	–	0.03%	222
2013 Q2	$176K	Buy	+28,750	New	+$148K	0.03%	208

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Baldwin Wealth Partners's AVDL Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 500 shares — an estimated $6.56K sold.

Baldwin Wealth Partners first reported a position in AVDL in Q2 2013 and held it in 38 quarters. The position peaked at $189K in Q3 2013. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

Baldwin Wealth Partners reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Baldwin Wealth Partners sold 500 Avadel Pharmaceuticals shares in Q4 2024, an estimated $6.56K.
Baldwin Wealth Partners first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 38 quarters.
Baldwin Wealth Partners's Avadel Pharmaceuticals position peaked at $189K in Q3 2013.
159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.